Rhythm Pharmaceuticals Inc. – Filings and Transcripts

NASDAQ: RYTM
Share price (7/21/26): $106.60
Market cap (7/21/26): $7.306 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

ended 03/31/25 Q1

Prospectuses and Registrations Filter

Registration of securities for employees

Registration of securities for employees

Automatic shelf registration

Registration of securities for employees

Prospectus supplement for primary offering

Ownership Filter

Garfield Alastair

Jean Christophe

McGirr David W J

Tetrault Lynn A.

Arbuckle Stuart A

News Filter

Shareholder Vote Results

Presents Positive Interim Six-Month Data From Phase 2 Trial of Setmelanotide in Patients With Prader-Willi Syndrome (PWS) at ENDO 2026

Reports First Quarter 2026 Financial Results and Business Update

Announces Changes to Board of Directors

Receives Positive CHMP Opinion for IMCIVREE® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients With Acquired Hypothalamic Obesity Due to Hypothalamic Injury or Impairment

Proxies Filter

Additional info about upcoming vote

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Other Filter

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission

Notice of effectiveness